Table 3

Summary of safety events (safety population)*

Variable, n (%)Secukinumab (n=28)Placebo (n=14)
Any AE26 (92.9)11 (78.6)
SAEs4 (14.3)1 (7.1)
Most common AEs†
 Nasopharyngitis7 (25.0)5 (35.7)
 Headache6 (21.4)1 (7.1)
 Nausea4 (14.3)1 (7.1)
 Dizziness4 (14.3)0 (0.0)
 Fatigue3 (10.7)0 (0.0)
 Diarrhoea3 (10.7)1 (7.1)
 Pruritus3 (10.7)1 (7.1)
 Myalgia3 (10.7)0 (0.0)
 Cough3 (10.7)0 (0.0)
 Vertigo1 (3.6)3 (21.4)
  • *Data for safety population (all patients who received the study medication regardless of treatment assignment).

  • †Only AEs occurring in three or more patients in any group are presented.

  • AE, adverse event; SAE, serious adverse event.